RESUMO
Background Since the increasing prevalence of type 2 diabetes mellitus (T2DM), heart failure coexisting with it has had a significant impact on clinical management and prognosis. Patients with T2DM and heart failure with reduced ejection fraction (HFrEF) have increased mortality and morbidity. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is widely acknowledged to reduce cardiovascular risk in T2DM patients. We wanted to assess the composite outcomes of heart failure, cardiovascular death, and hospitalization following the start of empagliflozin therapy in the Saudi population. Methods This is a retrospective observational study conducted at King Fahad Armed Forces Hospital-Jeddah. We included patients aged 18 or older, male or female, with T2DM with HFrEF <40% and with a risk of cardiovascular events who were treated with empagliflozin 25 mg once daily as combination therapy and patients using other diabetic agents without empagliflozin as the comparative group. Results A total of 195 patients with T2DM and HFrEF who were at high risk for cardiovascular (CV) events were included in the study. Regarding gender, most of the patients (82.1%) were male with an average age of 61.28 ± 9.92. The patients were divided into 71 individuals who received empagliflozin and 124 who did not. When comparing the surgical procedure and comorbid status of the patients, coronary artery bypass graft (1.4%), coronary artery disease (5.6%), dyslipidemia (5.6%), and ischemic cardiomyopathy (0%) were found compared to the non-empagliflozin group. Meanwhile, hypertension was found to be 71.8% and ischemic heart disease was 50.7% in empagliflozin patients. Furthermore, only dyslipidemia differed significantly (p <0.001) between the empagliflozin and non-empagliflozin groups of patients. However, no significant differences were observed between the average low-density lipoprotein (p = 0.990) and high-density lipoprotein (p = 0.399). There was no significant difference observed in the primary outcome of CV deaths or hospital admission of patients between empagliflozin and non-empagliflozin. No deaths were reported in either of the comparative groups in our study. Conclusion In this study, there was no significant difference observed in hospital admission of the patients between the empagliflozin and non-empagliflozin groups. No cardiovascular mortality was reported in the study population. Further matched group comparative studies or placebo-controlled studies are required to compare the existing evidence of the impact of empagliflozin on T2DM patients with HFrEF and at high risk for CV deaths or hospital admission.
RESUMO
OBJECTIVES: This work investigated the impacts of food habits and lifestyle on the prevalence of overweight (OW) and obesity (OB) among health sciences students (HSS) at Taif University, KSA. METHODS: A cross-sectional survey was conducted with 228 HSS in a university setting using a food frequency questionnaire. Body mass index (BMI) was used to assess weight gain, and waist circumference (W_C) was employed for the assessment of abdominal adiposity. RESULTS: The prevalences of OW and OB were 25.9% and 10.9%, respectively, with an overall prevalence of 36.8%. All demographic variables had an insignificant (P > 0.05) effect on W_C. There were significant links between gender, academic year and discipline and BMI (P < 0.05). Smoking, stress, duration of TV viewing, daylight and night sleep had an effect on BMI and W_C but were statistically insignificant (P > 0.05). Breakfast, light meals, eating with a family, fast food, and regular and diet soft drinks had insignificant impacts on BMI (P > 0.05). A considerable relationship was observed between consumption of liver and BMI (P < 0.05), while meat, egg, milk, fruit and vegetable, and grain intake had no significant effect on BMI (P > 0.05). All varieties of foods had no significant impact on W_C (P > 0.05). CONCLUSIONS: The prevalence of OW and OB was 36.8%. The participants' gender, academic year, discipline, and liver intake had a significant impact on BMI. All other tested variables showed a nonsignificant relationship with W_C.
